NO20010805L - Immunogent <beta>-propionamidokoblet polysakkarid-proteinkonjugat anvendbart som vaksine, fremstilt ved anvendelse av et N-akryloylert polysakkarid - Google Patents
Immunogent <beta>-propionamidokoblet polysakkarid-proteinkonjugat anvendbart som vaksine, fremstilt ved anvendelse av et N-akryloylert polysakkaridInfo
- Publication number
- NO20010805L NO20010805L NO20010805A NO20010805A NO20010805L NO 20010805 L NO20010805 L NO 20010805L NO 20010805 A NO20010805 A NO 20010805A NO 20010805 A NO20010805 A NO 20010805A NO 20010805 L NO20010805 L NO 20010805L
- Authority
- NO
- Norway
- Prior art keywords
- polysaccharide
- propionamido
- beta
- immunogenic
- acryloylated
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 150000004676 glycans Chemical class 0.000 title abstract 2
- 229920001282 polysaccharide Polymers 0.000 title abstract 2
- 239000005017 polysaccharide Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9712098P | 1998-08-19 | 1998-08-19 | |
| US37691199A | 1999-08-18 | 1999-08-18 | |
| PCT/US1999/018982 WO2000010599A2 (fr) | 1998-08-19 | 1999-08-18 | Conjugue de proteine-polysaccharide immunogene a liaison beta-propionamido, utile comme vaccin etabli au moyen d'un polysaccharide n-acryloyle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20010805D0 NO20010805D0 (no) | 2001-02-16 |
| NO20010805L true NO20010805L (no) | 2001-04-03 |
Family
ID=26792625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010805A NO20010805L (no) | 1998-08-19 | 2001-02-16 | Immunogent <beta>-propionamidokoblet polysakkarid-proteinkonjugat anvendbart som vaksine, fremstilt ved anvendelse av et N-akryloylert polysakkarid |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040213804A1 (fr) |
| EP (1) | EP1109576B1 (fr) |
| JP (1) | JP2004505885A (fr) |
| KR (1) | KR100704826B1 (fr) |
| CN (1) | CN1263510C (fr) |
| AT (1) | ATE446107T1 (fr) |
| AU (1) | AU771330B2 (fr) |
| CA (1) | CA2340692A1 (fr) |
| CZ (1) | CZ2001622A3 (fr) |
| DE (1) | DE69941574D1 (fr) |
| HK (1) | HK1041825B (fr) |
| HU (1) | HUP0103100A3 (fr) |
| NO (1) | NO20010805L (fr) |
| NZ (1) | NZ509986A (fr) |
| WO (1) | WO2000010599A2 (fr) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01009452A (es) | 1999-03-19 | 2002-08-06 | Smithkline Beecham Biolog | Vacuna. |
| AU2001256970C1 (en) | 2000-03-31 | 2008-07-03 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
| IL153558A0 (en) * | 2000-06-20 | 2003-07-06 | Shire Biochem Inc | Streptococcus antigens |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2004011027A1 (fr) * | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Vaccins multivalents chimeres a conjugue polysaccharidique |
| ES2775098T3 (es) | 2002-10-11 | 2020-07-23 | Glaxosmithkline Biologicals Sa | Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| CN102319427A (zh) | 2003-01-30 | 2012-01-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
| MXPA05014015A (es) * | 2003-06-23 | 2006-03-17 | Baxter Int | Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo. |
| CN103357002A (zh) | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| US7422755B2 (en) * | 2004-01-15 | 2008-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Antimultiorganism glycoconjugate vaccine |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| EP2272531A3 (fr) | 2004-04-30 | 2011-04-13 | Novartis Vaccines and Diagnostics S.r.l. | Intégration du vaccin conjugué de méningococcus |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| JP5297800B2 (ja) | 2005-06-27 | 2013-09-25 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| CA2621578C (fr) * | 2005-09-05 | 2014-07-22 | Glaxosmithkline Biologicals S.A. | Essai d'activite bactericide serique pour des antiserums specifiques de n. meningitidis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| KR101441368B1 (ko) | 2005-12-22 | 2014-09-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 폐렴구균 다당류 컨쥬게이트 백신 |
| CA2636983A1 (fr) * | 2006-01-13 | 2007-07-26 | Baxter International Inc. | Procede de purification de polysaccharides |
| WO2007092299A2 (fr) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Conjugués ciblés et radiation |
| ATE554788T1 (de) | 2006-03-22 | 2012-05-15 | Novartis Ag | Schemata zur immunisierung mit meningokokken- konjugaten |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| EA015964B1 (ru) | 2006-09-07 | 2012-01-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| CN102978185B (zh) * | 2007-01-18 | 2015-02-11 | 建新公司 | 包含氨基氧基基团的寡糖及其轭合物 |
| AR066376A1 (es) | 2007-05-02 | 2009-08-12 | Glaxosmithkline Biolog Sa | Vacuna |
| AU2008265767B2 (en) * | 2007-06-20 | 2014-11-13 | Pfizer Ireland Pharmaceuticals | Modified polysaccharides for conjugate vaccines |
| EP2167120A2 (fr) | 2007-06-26 | 2010-03-31 | GlaxoSmithKline Biologicals S.A. | Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| JP5701058B2 (ja) | 2007-10-19 | 2015-04-15 | ノバルティス アーゲー | 髄膜炎菌ワクチン処方物 |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| EP2245048B1 (fr) | 2008-02-21 | 2014-12-31 | Novartis AG | Polypeptides fhbp à méningocoques |
| EP2349520B1 (fr) | 2008-10-27 | 2016-05-25 | GlaxoSmithKline Biologicals SA | Procédé de purification pour l'hydrate de carbone de streptocoque de groupe a |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| NZ593674A (en) | 2008-12-17 | 2013-03-28 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| BRPI1009829A2 (pt) | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
| EP2411048B1 (fr) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Protéine de liaison du facteur h méningococcique utilisée comme adjuvant |
| EP2419129A2 (fr) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions pour l'immunisation contre staphylococcus aureus |
| WO2010141312A2 (fr) | 2009-06-01 | 2010-12-09 | Wake Forest University Health Sciences | Protéines de fusion flagelline et conjugués comprenant des antigènes pneumocoques et leurs procédés d'utilisation |
| NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| CA2773637A1 (fr) | 2009-09-10 | 2011-03-17 | Novartis Ag | Vaccins combines contre les maladies des voies respiratoires |
| CA2776004A1 (fr) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression de polypeptides fhbp meningococciques |
| AU2010352695B2 (en) | 2009-09-30 | 2014-08-21 | Glaxosmithkline Biologicals S.A. | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| JP5960055B2 (ja) | 2009-10-27 | 2016-08-02 | ノバルティス アーゲー | 改変髄膜炎菌ｆＨＢＰポリペプチド |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
| WO2012072769A1 (fr) | 2010-12-01 | 2012-06-07 | Novartis Ag | Epitopes rrgb de pneumocoque et combinaisons de variantes |
| EP2655389A2 (fr) | 2010-12-24 | 2013-10-30 | Novartis AG | Composés |
| CN102526724B (zh) * | 2011-01-14 | 2015-07-22 | 四川大学 | 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途 |
| ES2681698T3 (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| LT3106176T (lt) | 2011-12-06 | 2018-01-10 | Valneva Austria Gmbh | Aliuminio junginiai, skirti naudoti terapijoje ir vakcinose |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| US10596246B2 (en) | 2011-12-29 | 2020-03-24 | Glaxosmithkline Biological Sa | Adjuvanted combinations of meningococcal factor H binding proteins |
| CN104159603A (zh) | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| KR101452830B1 (ko) * | 2012-04-06 | 2014-10-21 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
| CA2874210A1 (fr) | 2012-05-22 | 2013-11-28 | Novartis Ag | Conjugue de serogroupe x de meningocoque |
| WO2014037472A1 (fr) | 2012-09-06 | 2014-03-13 | Novartis Ag | Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p |
| AU2013326584B2 (en) | 2012-10-02 | 2016-12-01 | Glaxosmithkline Biologicals Sa | Nonlinear saccharide conjugates |
| CA2886938A1 (fr) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines |
| KR20150100665A (ko) | 2012-11-30 | 2015-09-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 슈도모나스 항원 및 항원 조합 |
| ES2670863T3 (es) | 2013-02-01 | 2018-06-01 | Glaxosmithkline Biologicals Sa | Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll |
| EA031393B1 (ru) | 2013-05-01 | 2018-12-28 | Глэксо Груп Лимитед | Композиции и способы модулирования экспрессии hbv и ttr |
| EP3041502A2 (fr) | 2013-09-08 | 2016-07-13 | Pfizer Inc. | Compositions utilisables contre neisseria meningitidis et procédés associés |
| AU2015222121B2 (en) | 2014-02-28 | 2018-01-18 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| EP3034516A1 (fr) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification de polysaccharides capsulaires de streptocoques |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2017120524A1 (fr) * | 2016-01-07 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Synthèse enzymatique définie d'analogues du lipide a |
| MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
| US12161707B2 (en) | 2016-09-02 | 2024-12-10 | Glaxosmithkline Biologicals Sa | Vaccines for Neisseria gonorrhoeae |
| US20210108002A1 (en) | 2016-12-06 | 2021-04-15 | Glaxosmithkline Biologicals Sa | Purification Process For Capsular Polysaccharide |
| JP7010961B2 (ja) | 2017-01-31 | 2022-02-10 | ファイザー・インク | 髄膜炎菌組成物およびその方法 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN111491662A (zh) * | 2017-12-19 | 2020-08-04 | 阿尔伯塔大学理事会 | 产气荚膜梭菌表面聚糖及其应用 |
| EP3607967A1 (fr) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Polypeptides modifiés du méningocoque fhbp |
| WO2020165711A1 (fr) | 2019-02-11 | 2020-08-20 | Pfizer Inc. | COMPOSITIONS DE NEISSERIA MENINGITIDIS<i /> ET PROCÉDÉS ASSOCIÉES |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| EP4446336A3 (fr) * | 2019-09-23 | 2025-06-25 | Koranex Capital | Néoglycoconjugués utilisés comme vaccins et outils thérapeutiques |
| EP4034157A1 (fr) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Compositions de neisseria meningitidis et méthodes associées |
| EP3799884A1 (fr) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Compositions immunogènes |
| EP4107192A1 (fr) | 2020-02-21 | 2022-12-28 | Pfizer Inc. | Purification de saccharides |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| WO2022084852A1 (fr) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Procédés de purification de polysaccharides bactériens |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| WO2024201324A2 (fr) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (fr) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées |
| WO2025021704A1 (fr) | 2023-07-21 | 2025-01-30 | Glaxosmithkline Biologicals Sa | Vaccin |
| WO2025057078A1 (fr) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Compositions immunogènes adjuvantées comprenant des antigènes saccharidiques capsulaires pneumococciques conjugués et leurs utilisations |
| WO2025186705A2 (fr) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) * | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4727136A (en) * | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
| US5192540A (en) * | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
| NL8802046A (nl) * | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| DE69019164T2 (de) * | 1989-12-14 | 1995-09-07 | National Research Council Of Canada, Ottawa, Ontario | Verbessertes meningokokkale polysaccharidkonjugatvakzin. |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5445817A (en) * | 1992-08-21 | 1995-08-29 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines |
| US5554730A (en) * | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
| US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| US5780606A (en) * | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
| US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
-
1999
- 1999-08-18 WO PCT/US1999/018982 patent/WO2000010599A2/fr not_active Ceased
- 1999-08-18 NZ NZ509986A patent/NZ509986A/en unknown
- 1999-08-18 DE DE69941574T patent/DE69941574D1/de not_active Expired - Lifetime
- 1999-08-18 KR KR1020017002108A patent/KR100704826B1/ko not_active Expired - Fee Related
- 1999-08-18 AT AT99945115T patent/ATE446107T1/de not_active IP Right Cessation
- 1999-08-18 HK HK02103707.6A patent/HK1041825B/zh not_active IP Right Cessation
- 1999-08-18 CN CNB998121703A patent/CN1263510C/zh not_active Expired - Fee Related
- 1999-08-18 EP EP99945115A patent/EP1109576B1/fr not_active Expired - Lifetime
- 1999-08-18 CA CA002340692A patent/CA2340692A1/fr not_active Abandoned
- 1999-08-18 HU HU0103100A patent/HUP0103100A3/hu unknown
- 1999-08-18 JP JP2000565919A patent/JP2004505885A/ja active Pending
- 1999-08-18 CZ CZ2001622A patent/CZ2001622A3/cs unknown
- 1999-08-18 AU AU57800/99A patent/AU771330B2/en not_active Ceased
-
2001
- 2001-02-16 NO NO20010805A patent/NO20010805L/no not_active Application Discontinuation
-
2004
- 2004-01-20 US US10/761,498 patent/US20040213804A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE446107T1 (de) | 2009-11-15 |
| WO2000010599A8 (fr) | 2000-08-10 |
| HUP0103100A3 (en) | 2005-11-28 |
| AU771330B2 (en) | 2004-03-18 |
| HK1041825B (zh) | 2007-02-23 |
| US20040213804A1 (en) | 2004-10-28 |
| WO2000010599A3 (fr) | 2000-06-22 |
| JP2004505885A (ja) | 2004-02-26 |
| KR100704826B1 (ko) | 2007-04-09 |
| NZ509986A (en) | 2003-10-31 |
| AU5780099A (en) | 2000-03-14 |
| CN1323221A (zh) | 2001-11-21 |
| HK1041825A1 (en) | 2002-07-26 |
| DE69941574D1 (de) | 2009-12-03 |
| CN1263510C (zh) | 2006-07-12 |
| KR20010072776A (ko) | 2001-07-31 |
| CA2340692A1 (fr) | 2000-03-02 |
| EP1109576B1 (fr) | 2009-10-21 |
| EP1109576A2 (fr) | 2001-06-27 |
| WO2000010599A2 (fr) | 2000-03-02 |
| NO20010805D0 (no) | 2001-02-16 |
| CZ2001622A3 (cs) | 2002-01-16 |
| HUP0103100A2 (hu) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20010805L (no) | Immunogent <beta>-propionamidokoblet polysakkarid-proteinkonjugat anvendbart som vaksine, fremstilt ved anvendelse av et N-akryloylert polysakkarid | |
| DK1051506T4 (da) | Fremgangsmåder til ekstraktion og isolering af bakterielle kapselpolysaccharider til anvendelse som vacciner eller bundet til proteiner som konjugatvacciner | |
| NO2011019I1 (no) | Vaksine omfattende antigenet PRP-T koplet til et tetanus anatoksin | |
| MA30065B1 (fr) | Vaccin | |
| RU2009108660A (ru) | Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов | |
| HUP0301413A1 (hu) | Vakcinakészítmények | |
| DK593285A (da) | Polysaccharidforbindelse og fremgangsmaade til fremstilling deraf | |
| WO2000056358A3 (fr) | Vaccin | |
| CA2071811A1 (fr) | Vaccin conjugue de polysaccharine meningoccocique | |
| IE840197L (en) | Polysaccharide protein conjugate vaccine | |
| GR3035081T3 (en) | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections | |
| AU8483391A (en) | Improved oligosaccharide conjugate vaccines | |
| WO2008011201A3 (fr) | Procédé de production d'un vaccin contre la méningite à méningocoques pour les sérotypes a,c,y, et w-135 de neisseria meningitidis | |
| FI932626A0 (fi) | Av en patogenisk aemne haerledande antigenisk polysackarid deriverad oligosackarid | |
| BRPI0606523A2 (pt) | vacinação meningocóccica conjugada | |
| ATE285790T1 (de) | Herstellungsverfahren von festphasekonjugateimpfstoffen | |
| AU3313789A (en) | Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine | |
| Brigden et al. | Structural studies of acidic glucomannans from strains of Serratia marcescens O14 and O6 | |
| TR200002974T2 (tr) | Bruselloza karşı canlı aşı | |
| EP0320942A3 (fr) | Polysaccharides et composés macromoléculaires contenant ces polysaccharides | |
| DE69615537D1 (en) | Helicobacter pylori antigen | |
| RU2001107132A (ru) | Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины, который получают с помощью n-акрилоилированного полисахарида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |